A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

NCT05600998 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Clear Cell Carcinoma

Interventions

DRUG: Camrelizumab

Sponsor

Peking University Third Hospital